TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39615342

Group type: EXPERIMENTAL
Intervention: COVIVAC 3 μg
Number of subjects: 374

Group type: EXPERIMENTAL
Intervention: COVIVAC 6 μg
Number of subjects: 374

Group type: COMPARATOR
Intervention: VAXZEVRIA
Number of subjects: 374
Study: 39615398

Group type: EXPERIMENTAL
Intervention: 12-month intervention integrating a Diabetes Prevention Program-based behavioral weight loss treatment with problem-solving therapy for depression
Number of subjects: 409

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 409
Study: 39615412

Group type: EXPERIMENTAL
Intervention: HA-PCI
Number of subjects: 318

Group type: COMPARATOR
Intervention: PCI
Number of subjects: 318
Study: 39615435

Group type: EXPERIMENTAL
Intervention: eNose measurements
Number of subjects: 160
Study: 39615484

Group type: EXPERIMENTAL
Intervention: Toripalimab plus anlotinib
Number of subjects: 40
Study: 39615497

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiotherapy (SBRT) to the primary tumour (50-54 Gy in three to five fractions) followed by standard radiotherapy (up to 60 Gy in 30 2 Gy fractions) to the involved lymph nodes with concurrent platinum doublet chemotherapy (either paclitaxel 50 mg/m2).
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Consolidation durvalumab (immunotherapy).
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Treatment-related adverse events.
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Treatment-related deaths.
Number of subjects: 61
Study: 39615502

Group type: EXPERIMENTAL
Intervention: Pooled-BENRA (benralizumab with or without prednisolone)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Prednisolone alone (PRED group)
Number of subjects: 158
Study: 39615582

Group type: EXPERIMENTAL
Intervention: SurVeil PCB
Number of subjects: 446

Group type: COMPARATOR
Intervention: IN.PACT Admiral PCB
Number of subjects: 446
Study: 39615596

Group type: EXPERIMENTAL
Intervention: Pattern A (higher baseline, amplitude, frequency, and damping)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Pattern A
Number of subjects: 159
Study: 39615618

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT; acetyl-salicylic-acid 100mg plus clopidogrel 75mg daily)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Single antiplatelet (SAPT; clopidogrel 75mg) plus DOAC (rivaroxaban 15mg)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy (DAPT)
Number of subjects: 62
Study: 39615802

Group type: EXPERIMENTAL
Intervention: Standardized metric for histologic airway mucosa assessments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tissue collection methods and histological assessment methods
Number of subjects: 0
Study: 39615889

Group type: EXPERIMENTAL
Intervention: 1 weekly IA injection of 5 mL PRP for 3 weeks
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo (saline solution)
Number of subjects: 210
Study: 39615886

Group type: EXPERIMENTAL
Intervention: NSAIDs
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Age (per year)
Number of subjects: 88
Study: 39615936

Group type: EXPERIMENTAL
Intervention: Mindfulness-based training intervention
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 60
Study: 39616189

Group type: EXPERIMENTAL
Intervention: Alteplase treatment
Number of subjects: 616
Study: 39616365

Group type: EXPERIMENTAL
Intervention: FallFitness exercise program (multicomponent exercise program delivered weekly for 8 weeks)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 101
Study: 39616375

Group type: EXPERIMENTAL
Intervention: Friends in Nature intervention
Number of subjects: 0
Study: 39616603

Group type: EXPERIMENTAL
Intervention: 2 doses of HepB-CpG vaccine (n=174)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: 3 doses of HepB-CpG vaccine (n=169)
Number of subjects: 561

Group type: COMPARATOR
Intervention: 3 doses of HepB-alum vaccine (n=165)
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: 3 doses of HepB-CpG vaccine
Number of subjects: 561

Group type: EXPERIMENTAL
Intervention: 2 doses of HepB-CpG vaccine
Number of subjects: 561
Study: 39617017

Group type: EXPERIMENTAL
Intervention: CTX130 (volamcabtagene durzigedleucel)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: CTX130 (volamcabtagene durzigedleucel) at dose level 3 and higher
Number of subjects: 39
Study: 39617030

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human prourokinase (15 mg bolus followed by 20 mg infusion within 30 min)
Number of subjects: 1552

Group type: EXPERIMENTAL
Intervention: Intravenous recombinant human prourokinase
Number of subjects: 1552

Group type: COMPARATOR
Intervention: Intravenous alteplase (0.9 mg per kg, maximum dose 90 mg; 10% bolus followed by remainder as infusion over 60 min)
Number of subjects: 1552

Group type: COMPARATOR
Intervention: Intravenous alteplase
Number of subjects: 1552
Study: 39617060

Group type: EXPERIMENTAL
Intervention: Faricimab 6.0 mg up to every 16 weeks after 4 initial doses every 4 weeks (Q4W)
Number of subjects: 1329

Group type: COMPARATOR
Intervention: Aflibercept 2.0 mg every 8 weeks after 3 initial doses given every 4 weeks (Q4W)
Number of subjects: 1329

Group type: EXPERIMENTAL
Intervention: Faricimab
Number of subjects: 1329

Group type: COMPARATOR
Intervention: Aflibercept
Number of subjects: 1329
Study: 39617145

Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine (MIRV) 6 mg/kg adjusted ideal body weight every 3 weeks until progressive disease, unacceptable toxicity, withdrawal of consent, or death
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine (MIRV)
Number of subjects: 79
Study: 39617302

Group type: EXPERIMENTAL
Intervention: Carbohydrate-reduced high-protein diet (CRHP, C/P/F = 30/30/40 E%)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Hypocaloric carbohydrate-reduced high-protein diet (CRHP)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Conventional diabetes diet (CD, C/P/F = 50/17/33 E%)
Number of subjects: 102
Study: 39617410

Group type: EXPERIMENTAL
Intervention: Apollo wearable device
Number of subjects: 25
Study: 39617464

Group type: EXPERIMENTAL
Intervention: Bipolar Disorder (BD)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Unipolar Disorder (UD)
Number of subjects: 106
Study: 39617530

Group type: EXPERIMENTAL
Intervention: BI 905677 at 2.8 mg/kg every 3 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: BI 905677 at 3.6 mg/kg every 3 weeks
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: BI 905677 (various doses)
Number of subjects: 37
Study: 39617535

Group type: EXPERIMENTAL
Intervention: BI 905681 (1.0, 2.5, 5.0, 7.0, and 8.5 mg/kg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: BI 905681
Number of subjects: 21
Study: 39617673

Group type: EXPERIMENTAL
Intervention: Oxylanthanum carbonate 1000 mg three times/day
Number of subjects: 80

Group type: COMPARATOR
Intervention: Lanthanum carbonate (LC) 1000 mg three times/day
Number of subjects: 80
Study: 39617826

Group type: EXPERIMENTAL
Intervention: Tinostamustine, 100 mg/m²
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Tinostamustine, RP2D (recommended Phase II dose)
Number of subjects: 10
Study: 39618085

Group type: EXPERIMENTAL
Intervention: Physiotherapy before and after ACL reconstruction (ACLR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physiotherapy after ACL reconstruction (ACLR) only
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prehabilitation and other preoperative variables
Number of subjects: 0
Study: 39618097

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: HIIT + Probiotics (HP)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: HIIT (H)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 47
Study: 39618195

Group type: EXPERIMENTAL
Intervention: Treatment according to subtype (esomeprazole for epigastric pain syndrome; itopride for postprandial distress syndrome; itopride with possible switch to esomeprazole at week 4)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Empirical proton pump inhibitor (esomeprazole only)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 180
Study: 39618204

Group type: EXPERIMENTAL
Intervention: Propofol administered before extubation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no propofol)
Number of subjects: 0
Study: 39618256

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks on background intranasal corticosteroids
Number of subjects: 724

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 724
Study: 39618477

Group type: EXPERIMENTAL
Intervention: Exogenous oral progesterone (200 mg twice daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 39618688

Group type: EXPERIMENTAL
Intervention: Vitamin D intervention
Number of subjects: 0
Study: 39618866

Group type: EXPERIMENTAL
Intervention: Low lung compliance (≤23.8 mL/cmH2O)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Higher lung compliance (above 23.8 mL/cmH2O)
Number of subjects: 141
Study: 39619400

Group type: EXPERIMENTAL
Intervention: Fourth-generation M-TEER system
Number of subjects: 95
Study: 39619495

Group type: EXPERIMENTAL
Intervention: SMART-U intervention (12-week intensive educational sessions and 12-week remotely accessed telephone follow-up)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (eTAU) control group
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: SMART-U intervention
Number of subjects: 188
Study: 39620046

Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ) 160 mg every 2 weeks (Q2W; Weeks 0-10) then 320 mg Q4W (Weeks 12-44)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Certolizumab pegol (CZP) 400 mg Q2W (Weeks 0-4), then 200 mg Q2W (Weeks 6-10), 400 mg Q4W (Weeks 12-44)
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Bimekizumab (BKZ)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Certolizumab pegol (CZP)
Number of subjects: 76
Study: 39620153

Group type: EXPERIMENTAL
Intervention: Electroacupuncture combined with standard pharmacological treatment (EG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard pharmacological treatment with placebo acupuncture (CG)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo acupuncture (CG)
Number of subjects: 60
Study: 39620201

Group type: EXPERIMENTAL
Intervention: PNET HR+5 regimen (intensive pediatric chemotherapy)
Number of subjects: 18
Study: 39620432

Group type: EXPERIMENTAL
Intervention: Chemotherapy plus radiotherapy
Number of subjects: 3840

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 3840
Study: 39620470

Group type: EXPERIMENTAL
Intervention: User-operated audiometry (UAud group)
Number of subjects: 215

Group type: COMPARATOR
Intervention: Traditional audiometry (control group)
Number of subjects: 215
Study: 39620865

Group type: EXPERIMENTAL
Intervention: Transplant Center Search Tool (TCST)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Scientific Registry of Transplant Recipients website (SRTR)
Number of subjects: 68
Study: 39621093

Group type: EXPERIMENTAL
Intervention: GU RMS
Number of subjects: 599

Group type: EXPERIMENTAL
Intervention: LR GU RMS
Number of subjects: 599
Study: 39621100

Group type: EXPERIMENTAL
Intervention: 3-week online exposure-based intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 39621103

Group type: EXPERIMENTAL
Intervention: 1600 IU/day of vitamin D
Number of subjects: 2271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2271
Study: 39621227

Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 955
Study: 39621320

Group type: EXPERIMENTAL
Intervention: Multisetting air purification
Number of subjects: 79

Group type: COMPARATOR
Intervention: Sham purification
Number of subjects: 79
Study: 39621340

Group type: EXPERIMENTAL
Intervention: Generic text message refill reminders
Number of subjects: 9501

Group type: EXPERIMENTAL
Intervention: Behavioral nudge text refill reminders
Number of subjects: 9501

Group type: EXPERIMENTAL
Intervention: Behavioral nudge text refill reminders plus a fixed-message chatbot
Number of subjects: 9501

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 9501

Group type: COMPARATOR
Intervention: Generic text message refill reminders vs Usual care
Number of subjects: 9501

Group type: COMPARATOR
Intervention: Behavioral nudge text refill reminders vs Usual care
Number of subjects: 9501

Group type: COMPARATOR
Intervention: Behavioral nudge text refill reminders plus a fixed-message chatbot vs Usual care
Number of subjects: 9501
Study: 39621341

Group type: EXPERIMENTAL
Intervention: SHARING Choices intervention
Number of subjects: 22949

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 22949
Study: 39621368

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Health Education Control
Number of subjects: 449
Study: 39621369

Group type: EXPERIMENTAL
Intervention: Youth of color (Black and Latinx)
Number of subjects: 0

Group type: COMPARATOR
Intervention: White youth
Number of subjects: 0
Study: 39621372

Group type: EXPERIMENTAL
Intervention: HOLA intervention (n = 30)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Enhanced psychoeducation (Control)
Number of subjects: 60
Study: 39621373

Group type: EXPERIMENTAL
Intervention: Online, coached mindfulness intervention
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 111
Study: 39621405

Group type: EXPERIMENTAL
Intervention: E4W mobile health app
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group using default phone camera
Number of subjects: 32
Study: 39621424

Group type: EXPERIMENTAL
Intervention: Transcutaneous tibial nerve stimulation (TTNS)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Sham therapy
Number of subjects: 100
Study: 39621640

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models for mortality
Number of subjects: 132145

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models for myocardial infarction
Number of subjects: 132145

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models for pneumonia
Number of subjects: 132145

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models for acute renal failure
Number of subjects: 132145

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models for readmission
Number of subjects: 132145

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models for venous thromboembolism
Number of subjects: 132145

Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models for sepsis or septic shock
Number of subjects: 132145

Group type: EXPERIMENTAL
Intervention: Complication rates for bleeding requiring transfusion
Number of subjects: 132145

Group type: EXPERIMENTAL
Intervention: Complication rates for hospital readmission
Number of subjects: 132145

Group type: EXPERIMENTAL
Intervention: Complication rates for cardiac arrest and acute renal failure
Number of subjects: 132145
Study: 39621728

Group type: EXPERIMENTAL
Intervention: DMC laser diode (λ = 808 nm), 4J per point, 100mW of power, 1,016W/cm2, 8 sites in the vulvar region, four consecutive applications, weekly.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (laser turned off)
Number of subjects: 60
Study: 39621979

Group type: COMPARATOR
Intervention: Intravenous dexmedetomidine (n = 15)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Peribulbar dexmedetomidine (n = 31)
Number of subjects: 46
Study: 39622021

Group type: EXPERIMENTAL
Intervention: Video Remote Interpreting (VRI) during medical appointments
Number of subjects: 216

Group type: COMPARATOR
Intervention: Standard communication tools (informal interpretation, lip- or note-reading, mobile phone contact with interpreters) during medical appointments
Number of subjects: 216
Study: 39622165

Group type: EXPERIMENTAL
Intervention: AN+AD (Brentuximab Vedotin, Nivolumab, Doxorubicin, Dacarbazine)
Number of subjects: 57
Study: 39622410

Group type: EXPERIMENTAL
Intervention: Erlotinib (150 mg/day) plus Ramucirumab (10 mg/kg every two weeks)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo plus Erlotinib (150 mg/day)
Number of subjects: 449
Study: 39622468

Group type: EXPERIMENTAL
Intervention: CHW-led intervention program (PLAN)
Number of subjects: 576

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 576
Study: 39622570

Group type: EXPERIMENTAL
Intervention: Colonoscopy with personality assessment using the Big Five Inventory, General Anxiety Disorder 7-item scale, and Patient Health Questionnaire 9-item Depression Scale.
Number of subjects: 322

Group type: EXPERIMENTAL
Intervention: Colonoscopy with personality assessment.
Number of subjects: 322
Study: 39622571

Group type: EXPERIMENTAL
Intervention: AI-driven platform for CAD assessment using CCTA
Number of subjects: 4196
Study: 39622578

Group type: EXPERIMENTAL
Intervention: Optimisation to contemporary HFrEF medical therapy with sacubitril/valsartan
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cardiac magnetic resonance imaging (CMR)
Number of subjects: 49
Study: 39622823

Group type: EXPERIMENTAL
Intervention: Adjunctive rosuvastatin
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard tuberculosis treatment
Number of subjects: 24
Study: 39623189

Group type: EXPERIMENTAL
Intervention: SLNB/targeted axillary dissection
Number of subjects: 2407

Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 2407

Group type: EXPERIMENTAL
Intervention: Non-pCR in the breast
Number of subjects: 2407

Group type: EXPERIMENTAL
Intervention: Nonluminal pathology
Number of subjects: 2407

Group type: EXPERIMENTAL
Intervention: Age younger than 45 years
Number of subjects: 2407

Group type: EXPERIMENTAL
Intervention: cT3-T4, no breast pCR (non-pCR), ypN(+), nonluminal pathology
Number of subjects: 2407

Group type: EXPERIMENTAL
Intervention: ypN2 or ypN3 disease
Number of subjects: 2407
Study: 39623365

Group type: EXPERIMENTAL
Intervention: Mesoglycan (200 mg for the first 5 days, then 100 mg for the subsequent 35 days, twice daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Mesoglycan
Number of subjects: 50
Study: 39623426

Group type: EXPERIMENTAL
Intervention: ADSC spray therapy
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 39623502

Group type: EXPERIMENTAL
Intervention: Extended-release buprenorphine (XR-BUP) - single injection of a 28-day formulation within 72-hours of anticipated hospital discharge.
Number of subjects: 342

Group type: COMPARATOR
Intervention: Treatment as usual (TAU) - may consist of any MOUD other than XR-BUP.
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Extended-release buprenorphine (XR-BUP)
Number of subjects: 342
Study: 39623529

Group type: COMPARATOR
Intervention: Non-AE group (patients without adverse events)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: AE group (patients with adverse events)
Number of subjects: 32
Study: 39623757

Group type: EXPERIMENTAL
Intervention: Advanced systemic therapy (AST) including dupilumab and upadacitinib
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Advanced systemic therapy (AST)
Number of subjects: 436

Group type: COMPARATOR
Intervention: Conventional therapies
Number of subjects: 436
Study: 39624149

Group type: EXPERIMENTAL
Intervention: mHealth intervention with cognitive and behavioral therapeutic elements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 39624175

Group type: EXPERIMENTAL
Intervention: ACOT1 overexpression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ACOT1 silencing
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 39624188

Group type: EXPERIMENTAL
Intervention: Automatic pneumatic ventilation
Number of subjects: 514

Group type: COMPARATOR
Intervention: Bag-valve-mask ventilation
Number of subjects: 514
Study: 39624459

Group type: EXPERIMENTAL
Intervention: Apomorphine treatment (30-day subcutaneous administration)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Apomorphine treatment
Number of subjects: 13
Study: 39624518

Group type: EXPERIMENTAL
Intervention: simoctocog alfa (Nuwiq)
Number of subjects: 28
Study: 39624736

Group type: EXPERIMENTAL
Intervention: Topical OA 0.5%
Number of subjects: 48

Group type: COMPARATOR
Intervention: Topical retinol 0.5%
Number of subjects: 48
Study: 39624747

Group type: EXPERIMENTAL
Intervention: Microwave treatment (Swift device)
Number of subjects: 0
Study: 39624833

Group type: EXPERIMENTAL
Intervention: HAIC sequential TAE combined with tislelizumab and surufatinib
Number of subjects: 0
Study: 39624892

Group type: EXPERIMENTAL
Intervention: Patient-specific out-of-pocket (OOP) cost estimates provided during encounters
Number of subjects: 247

Group type: COMPARATOR
Intervention: Standard care without patient-specific OOP cost estimates
Number of subjects: 247
Study: 39624908

Group type: EXPERIMENTAL
Intervention: Subcutaneous ICD (S-ICD)
Number of subjects: 849

Group type: COMPARATOR
Intervention: Transvenous ICD (TV-ICD)
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Both S-ICD and TV-ICD
Number of subjects: 849

Group type: EXPERIMENTAL
Intervention: Intervention after first IAS
Number of subjects: 849
Study: 39624922

Group type: EXPERIMENTAL
Intervention: Higher HBcrAg levels at end of treatment (EOT)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Lower anti-HBc levels at EOT
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Higher HBcrAg/anti-HBc ratio at EOT
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Higher HBcrAg levels at follow-up week 6 (FUW6)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Lower anti-HBc levels at FUW6
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Higher HBcrAg/anti-HBc ratio at FUW6
Number of subjects: 78
Study: 39624936

Group type: EXPERIMENTAL
Intervention: Core Laboratory (ECL) assessment
Number of subjects: 1118

Group type: COMPARATOR
Intervention: Center-reported echocardiographic assessment
Number of subjects: 1118
Study: 39625044

Group type: EXPERIMENTAL
Intervention: Maternal lymphocyte subpopulations characterized by flow cytometry
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Combination of two consecutive markers
Number of subjects: 167